[GELUM oral-rd: blood pH regulator and oxygen activator. Documentation No.27].
GELUM oral-rd contains a potassium iron phosphate-potassium iron citrate complex, lactic acid and vitamins. It is recommended in oxygen deficiency states, tissue and tumour diseases and more recently as an adjunct to tumour therapy. The recommended dosage is 20 drops three times daily, to be taken for 5 to 10 years following cancer surgery. No side effects are stated. The daily cost of treatment is DM - .60 to DM 1.35. Manufacturer: Laboratorium pharmazeutischer Erzeugnisse Dr. Elten und Sohn was founded in 1938 and was renamed Dreluso Pharmazeutika Dr. Elten & Sohn in 1948, Oldendorf, FRG. Malignancies require a pathological alkaline milieu for growth; the associated increase in oxygen deficiency is caused by an unbalanced diet and carcinogens. GELUM oral-rd restores an optimum milieu and at the same time activates the lymph system, thereby providing the basis for all other tumour therapies. In transplant tumours and in Meth-A mouse fibrosarcoma, only prophylactic administration of GELUM oral-rd lengthened survival time or reduced tumour induction. Lymph node hyperplasia and giant cells in the spleen, occurring only in the pretreated animals, are also interpreted as nonspecific activation of the body's defence system. The clinical investigations are more anecdotal in nature, and the basic documentation and case studies are inadequate. In the prospective, randomized trial in 72 patients suffering from carcinoma of the gastrointestinal tract, the conclusion of efficacy is questionable on account of the incongruence between the group receiving the active drug and the control group. GELUM oral-rd is not registered in Switzerland at the IKS.